Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & workings
1.2.1 Data collection
1.3 Forecast calculations
1.4 COVID-19 impact analysis at global level
1.5 Data sources
1.5.1 Primary
1.5.2 Secondary
1.5.2.1 Paid sources
1.5.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Antibody therapy market 3600 synopsis, 2018 - 2032 (USD Million)
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Type trends
2.1.4 End-use trends
Chapter 3 Antibody Therapy Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of chronic and infectious disease worldwide
3.2.1.2 Growing R&D activities
3.2.1.3 High rate of adoption and approval in the U.S. and Europe
3.2.1.4 Booming biologics industry
3.2.1.5 Rising applications of antibody therapy
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of some monoclonal antibody therapeutics
3.2.2.2 Complex manufacturing processes and logistical challenges
3.3 Growth potential analysis
3.3.1 By type
3.3.2 By end-use
3.4 COVID- 19 impact analysis
3.5 Pipeline products
3.5.1 Monoclonal antibodies
3.5.2 Antibody drug conjugates
3.6 Regulatory landscape
3.7 Porter's analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company market share analysis, 2022
4.3 Competitive analysis of major market players, 2022
4.4 Company positioning matrix, 2022
4.5 Strategy outlook matrix, 2022
Chapter 5 Antibody Therapy Market Size and Forecast, By Type, 2018-2032 (USD Million)
5.1 Key trends, by type
5.2 Monoclonal antibodies (mAbs)
5.2.1 Oncology
5.2.2 Autoimmune diseases
5.2.3 Infectious diseases
5.2.4 Other monoclonal antibodies (mAbs)
5.3 Antibody-drug conjugates (ADCs)
Chapter 6 Antibody Therapy Market Size and Forecast, By End-Use, 2018-2032 (USD Million)
6.1 Key trends, by end-use
6.2 Hospitals
6.3 Specialty centers
6.4 Other end-users
Chapter 7 Antibody Therapy Market Size and Forecast, By Region, 2018-2032 (USD Million)
7.1 Key trends, by region
7.2 North America
7.2.1 U.S.
7.2.2 Canada
7.3 Europe
7.3.1 Germany
7.3.2 UK
7.3.3 France
7.3.4 Italy
7.3.5 Spain
7.3.6 Rest of Europe
7.4 Asia Pacific
7.4.1 China
7.4.2 Japan
7.4.3 India
7.4.4 Australia
7.4.5 Singapore
7.4.6 Rest of Asia Pacific
7.5 Latin America
7.5.1 Brazil
7.5.2 Mexico
7.5.3 Argentina
7.5.4 Rest of Latin America
7.6 Middle East & Africa
7.6.1 South Africa
7.6.2 Saudi Arabia
7.6.3 UAE
7.6.4 Kuwait
7.6.5 Egypt
7.6.6 Rest of Middle East & Africa
Chapter 8 Company Profiles
8.1 F. Hoffmann-La Roche Ltd.
8.2 AbbVie, Inc.
8.3 Amgen Inc.
8.4 Bristol-Myers Squibb Company
8.5 Johnson & Johnson Services, Inc.
8.6 Seagen
8.7 Merck & Co., Inc.
8.8 Regeneron Pharmaceuticals Inc.
8.9 Novartis AG
8.10 AstraZeneca
8.11 Eli Lilly and Company
8.12 GlaxoSmithKline plc.
8.13 Takeda Pharmaceutical Company Ltd.
